Ketamine-for-OUD trial will publish preliminary data showing modest efficacy but insufficient to support a label expansion, reinforcing off-label risk concerns.

A clinical trial testing ketamine as a treatment for opioid addiction will publish early data showing it helps a little — but not enough to convince the FDA (the US drug regulator) to officially approve it for that use. This matters because without an official approval, doctors prescribing ketamine for opioid addiction are doing so 'off-label' — meaning outside the approved use — which creates legal and insurance complications and makes it harder for patients to access.

OUD is a graveyard for adjuncts; ketamine's abuse liability makes FDA cautious. Data will underwhelm relative to advocacy claims.